PPV23
PreclinicalBiologic
CanSino Biologics Inc.PPV23 is one of 5 biologic programs targeting Diphtheria. It is currently in Preclinical.
1
Indications
9
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Diphtheria
#DrugCompanyPhaseTrials
1BCG Vaccine
GGynecologic Oncology Group
Phase 3
Dtacp
CChangchun BCHT Biotechnology Co.
Phase 3
Tdap Vaccine
SanofiPhase 1
Pentavalent Vaccine
GSKPreclinical
PPV23
CanSino Biologics Inc.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Memory2 trials
Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients
Unknown status·—·Phase 4·NCT03041051·40 enrolled
Clinical Trial2 trials
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PPV23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company